A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Bossi P.; Miceli R.; Locati L. D.; Ferrari D.; Vecchio S.; Moretti G.; Denaro N.; Caponigro F.; Airoldi M.; Moro C.; Vaccher E.; Sponghini A.; Caldara A.; Rinaldi G.; Ferrau F.; Nole F.; Lo Vullo S.; Tettamanzi F.; Hollander L.; Licitra L.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

【24h】

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

机译：一种随机的，相2研究Cetuximab加顺铂，具有或不含紫杉醇，用于患有头部和颈部复发和/或转移性鳞状细胞癌的患者的一线治疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin with/without paclitaxel (CetCis versus CetCisPac) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

机译：B490（Eudract＃2011-002564-24）是一种随机的，第2B阶段，非资治性研究，研究了一线甲磺酸的疗效和安全性与复发性和/或转移性鳞状细胞的患者的患者（Cetcis）（Cetcis对Cetcispac）的疗效和安全性头部和颈部（R / M SCCHN）的癌。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2017年第11期|共7页
作者
Bossi P.; Miceli R.; Locati L. D.; Ferrari D.; Vecchio S.; Moretti G.; Denaro N.; Caponigro F.; Airoldi M.; Moro C.; Vaccher E.; Sponghini A.; Caldara A.; Rinaldi G.; Ferrau F.; Nole F.; Lo Vullo S.; Tettamanzi F.; Hollander L.; Licitra L.;
展开▼
作者单位

Milan Univ Milan Head &

Neck Med Oncol Fdn IRCCS Ist Nazl Tumori I-20133 Milan Italy;

Fdn IRCCS Ist Nazl Tumori Clin Epidemiol &

Trial Org Milan Italy;

Milan Univ Milan Head &

Neck Med Oncol Fdn IRCCS Ist Nazl Tumori I-20133 Milan Italy;

Osped San Paolo Med Oncol Milan Italy;

IST Natl Canc Inst IRCCS San Martino Med Oncol Genoa Italy;

Azienda Osped Arcispedale Santa Maria Nuova IRCCS Med Oncol Reggio Emilia Italy;

St Croce &

Carle Univ Teaching Hosp Med Oncol Cuneo Italy;

Ist Nazl Tumori IRCCS Fdn Pascale Med Oncol Naples Italy;

Citta Salute &

Sci Hosp Turin Med Oncol Div 2 Turin Italy;

Azienda Osped Papa Giovanni XXIII Med Oncol Bergamo Italy;

Ctr Riferimento Oncol Med Oncol Aviano Italy;

AO Univ Maggiore della Carita Med Oncol Novara Italy;

Osped Santa Chiara Med Oncol Trento Italy;

AOU Policlin Paolo Giaccone Med Oncol Palermo Italy;

Osped San Vincenzo Med Oncol Taormina Italy;

Ist Europeo Oncol Med Oncol Milan Italy;

Fdn IRCCS Ist Nazl Tumori Clin Epidemiol &

Trial Org Milan Italy;

IRCCS Ist Ric Farmacol &

Mario Negri Oncol Milan Italy;

IRCCS Ist Ric Farmacol &

Mario Negri Oncol Milan Italy;

Milan Univ Milan Head &

Neck Med Oncol Fdn IRCCS Ist Nazl Tumori I-20133 Milan Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
cetuximab; R; M SCCHN; paclitaxel; cisplatin; EXTREME;

机译：香素蛋白;r;m scchn;paclitaxel;cisplatin;极端;

相似文献

外文文献
中文文献
专利

1. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [J] . Bossi P., Miceli R., Locati L. D., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第11期

机译：一种随机的，相2研究Cetuximab加顺铂，具有或不含紫杉醇，用于患有头部和颈部复发和/或转移性鳞状细胞癌的患者的一线治疗
2. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study [J] . Guigay J., Fayette J., Dillies A. F., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第9期

机译：西妥昔单抗，多西他赛和顺铂作为复发或转移性头颈部鳞状细胞癌患者的一线治疗：GORTEC II期多中心研究
3. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck [J] . Wirth Lori J., Dakhil Shaker, Kornek Gabriela, Oral oncology . 2016,第Null期

机译：合作伙伴：一项多西他赛/顺铂化疗联合或不联合帕尼单抗作为复发性或转移性头颈部鳞状细胞癌的一线治疗的开放式，随机，2期研究
4. Interstitial photodynamic therapy in combination with Cetuximab for recurrent head and neck squamous cell carcinoma [C] . Nestor Rigual, Ambujakshan Dildeep, Gal Shafirstein Conference on photonic therapeutics and diagnostics IX . 2013

机译：间质性光动力疗法联合西妥昔单抗治疗复发性头颈部鳞状细胞癌
5. Inflammatory mechanisms of chemokine receptor 7 expression in metastatic squamous cell carcinoma of the head and neck (SCCHN). [D] . Mburu, Yvonne K. 2011

机译：趋化因子受体7在头颈部转移性鳞状细胞癌（SCCHN）中表达的炎症机制。
6. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial) [O] . Georgios Tsakonas, Lena Specht, Claus Andrup Kristensen, 2020

机译：随机阶段II与西汀昔单抗与5-FU和顺铂或Carboplatin与Cetuximab一起研究。西妥昔单抗与紫杉醇和卡铂联合治疗头部和颈部复发或转移性鳞状细胞癌的患者（Cetmet试验）
7. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial) [O] . Georgios Tsakonas, Lena Specht, Claus Andrup Kristensen, 2020

机译：随机阶段II与西汀昔单抗与5-FU和顺铂或Carboplatin与Cetuximab一起研究。西妥昔单抗与紫杉醇和卡铂联合治疗头部和颈部复发或转移性鳞状细胞癌的患者（Cetmet试验）

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

摘要

著录项

相似文献

相关主题

期刊订阅